Novel clinical strategies for the treatment of pancreatic carcinoma

Trends in Molecular Medicine

Volumn 7, Issue 1, 2001, Pages 30-37

  Günzburg, Walter H ^a   Salmons, Brian ^b  

^a UNIVERSITY OF VETERINARY MEDICINE   (Austria)

^b Austrian Nordic Biotherapeutics AG   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

6 HYDROXYMETHYLACYLFULVENE; ANTINEOPLASTIC AGENT; AVICINE; CANCER VACCINE; CARCINOEMBRYONIC ANTIGEN MONOCLONAL ANTIBODY; CEA-CIDE; CGP 69846A; DIPHTHERIA TOXOID; EXATECAN; FLUOROURACIL; FOLINATE CALCIUM; GASTROIMMUNE; GBC 590; GEMCITABINE; HEAT SHOCK PROTEIN; HSPPC-96; IFOSFAMIDE; IRINOTECAN; ISIS 2503; NUCLEOSIDE ANALOG; PANCREAS ENZYME; PECTIN; RUBITECAN; SB 408075; TOPOTECAN; TROXACITABINE; UNCLASSIFIED DRUG; VIRUZILIN; 1,3 DIOXOLANE DERIVATIVE; ACYLFULVENE; COMPLEMENTARY DNA; CYTOCHROME P450 2B1; CYTOSINE; DEOXYCYTIDINE; DNA TOPOISOMERASE; DRUG DERIVATIVE; ENZYME INHIBITOR; GBC590; IMMUNOLOGICAL ADJUVANT; MONOCLONAL ANTIBODY; POLYAMINE; PROTEINASE; SESQUITERPENE; SPIRO COMPOUND; TISSUE EXTRACT; TUMOR PROTEIN; VIRULIZIN;

CANCER SURVIVAL; CAUSE OF DEATH; CLINICAL TRIAL; DRUG MECHANISM; DRUG POTENCY; DRUG TOLERABILITY; FEVER; GENE TARGETING; GENE THERAPY; HAIR LOSS; HUMAN; LIVER DYSFUNCTION; NAUSEA; NEUTROPENIA; PANCREAS CARCINOMA; REVIEW; SURVIVAL RATE; SURVIVAL TIME; VOMITING; BILE; BIOTRANSFORMATION; CANCER STEM CELL; CARCINOMA; DRUG ANTAGONISM; GENETICS; IMMUNOLOGY; MORTALITY; MULTICENTER STUDY; ONCOGENE RAS; PANCREAS TUMOR; PILOT STUDY; PROSPECTIVE STUDY; PROSTHESES AND ORTHOSES; TRANSPLANTATION; TUMOR SUPPRESSOR GENE;

ADJUVANTS, IMMUNOLOGIC; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BILE; BIOTRANSFORMATION; CANCER VACCINES; CARCINOMA; CLINICAL TRIALS; CYTOCHROME P-450 CYP2B1; CYTOSINE; DEOXYCYTIDINE; DIOXOLANES; DNA TOPOISOMERASES, TYPE I; DNA, ANTISENSE; ENDOPEPTIDASES; ENZYME INHIBITORS; GENE THERAPY; GENES, P53; GENES, RAS; HEAT-SHOCK PROTEINS; HUMANS; IFOSFAMIDE; MULTICENTER STUDIES; NEOPLASM PROTEINS; PANCREATIC NEOPLASMS; PECTINS; PILOT PROJECTS; POLYAMINES; PROSPECTIVE STUDIES; PROSTHESES AND IMPLANTS; SESQUITERPENES; SPIRO COMPOUNDS; TISSUE EXTRACTS; TUMOR STEM CELLS;

EID: 0034481404     PISSN: 14714914     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1471-4914(00)01865-7     Document Type: Review

References (59)

1. Cancer Statistics, 1998
2. Action of 2′,2′-difluorodeoxycytidine and 1-b-D-aribinofuranosylcytosine
3. Modulatory activity of 2′,2′-difluorodeoxycytidine on the phosphorylation and cytotoxicity of arabinosyl nucleosides
4. Evaluation of the antitumour activity of Gemcitabine
5. Improvements in survival and clinical benefit with Gemcitabine as first-line therapy for patients with advanced pancreas cancer - A randomized trial
6. An investigational new drug treatment program for patients with gemcitabine: Results for over 3000 patients with pancreatic carcinoma
7. Gemcitabine and 5-fluorouracil in advanced pancreatic cancer, a GISCAD phase II study
8. A phase I-II study of gemcitabine plus continuous infusion 5-fluorouracil in patients with advanced pancreatic cancer
9. Topoisomerase I poisons and suppressors as anticancer drugs
10. Alkyl esters of camptothecin and 9-nitrocamptothecin - Synthesis, in vitro pharmacokinetics, toxicity, and antitumor-activity
11. A study of 9-nitrocamptothecin (RFS-2000) in patients with advanced pancreatic cancer
12. A Phase-I and pharmacokinetic (Pk) study of DX-8951F, a novel hexacyclic camptothecin (CPT) analog, on a 30 minute infusion daily for 5 days every 3 week schedule
13. Phase-I and pharmacokinetic study of DX-8951F, a novel topoisomerase-I Inhibitor, using a 30 minute infusion weekly X-3 every 4 weeks
14. Phase-I and pharmacokinetic study of DX-8951F, a novel topoisomerase-1 inhibitor, using a 30 minute infusion every 3 weeks
15. Phase-I and pharmacokinetic (Pk) study of DX-8951F, a novel camptothecin analog, given as 30-minute infusion daily for 5 days
16. Clinical applications of the camptothecins
17. DX-8951F, a water-soluble camptothecin analog, exhibits potent antitumor-activity against a human lung-cancer call-line and its Sn-38-resistant variant
18. Polyamine metabolism as target for cancer chemoprevention
19. Troxacitabine (Bch-4556), a nucleoside analog with distinct stereochemical, pharmacological and pharmacokinetic characteristics is tolerable and active in Phase-I Studies - The NCI-CCTG experience
20. NCI-CCTG IND-103 - A Phase-I and pharmacokinetic (pk) study of the novel 1-nucleoside analog troxacitabine (Bch-4556) given every 21 days
21. Phase-I and pharmacokinetic (pk) study of troxacitabine (B-L-dioxoran-cytidine-Bch-4556) on a daily x 5-day every 4-week schedule
22. The new dioxolane, (-)-2′deoxy-3′-oxacytidine (BCH-4556,troxacitabine), has activity against pancreatic human tumor xenografts
23. A Phase I study of GBC-590 in patients with maligancy relapsing or refractory to standard therapy
24. Metabolism of antitumor hydroxymethylacylfulvene by rat-liver cytosol
25. Drug uptake and cellular targets of hydroxymethylacylfulvene
26. Efficacy of HMAF (MGI-114) in the MV522 metastatic lung carcinoma xenograft model nonresponsive to traditional anticancer agents
27. Antitumor activity of MGI 114 (6-hydroxymethylacylfulvene, HMAF), a semisynthetic derivative of illudin S, against adult and pediatric human tumor colony-forming units
28. Evaluation of pancreatic proteolytic enzyme treatment of adenocarcinoma of the pancreas, with nutrition and detoxification support
29. Identification of proliferating dendritic cell precursors in mouse blood
30. A phase I clinical trial of lethally irradiated allogeneic pancreatic tumor cells transfected with the GM-CSF gene for the treatment of pancreatic adenocarcinoma; pancreas cancer cell transfected with granulocyte-macrophage colony stimulating factor, used in cytokine-mediated gene therapy and immunotherapy
31. Immunotherapy of cancer
32. Superantigen-based immunotherapy: A phase I trial of PNU-214565, a monclonal antibody-staphylococcal enterotoxin A recombinant fusion protein, in advanced pancreatic and colorectal cancer
33. Phase II multicenter evaluation of prolonged murine monoclonal antibody 17-1A therapy in pancreatic carcinoma
34. Phase II trial of interferon gamma and monoclonal antibody 17-1A therapy in pancreatic carcinoma
35. Heat shock protein-peptide complexes as immunotherapy for human cancer
36. Ex vivo ras peptide vaccination in patients with advanced pancreatic cancer: Results of a phase I/II study
37. Gastrimmune raises antibodies that neutralize amidated and glycine-extended gastrin-17 and inhibit the growth of colon cancer
38. The p53 tumour suppressor gene
39. p53 function and dysfunction
40. Onyx-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic-agents
41. p53-dependent cell-death apoptosis is required for a productive adenovirus infection
42. Replication of Onyx-015, a potential anticancer adenoviras, is independent of p53 status in tumor-cells
43. p14ARF links the tumour suppressors Rb and p53
44. Onyx-015-Clinical data are encouraging
45. Liposome-mediated in vivo gene transfer of antisense K-ras construct inhibits pancreatic tumor dissemination in the murine peritoneal cavity
46. Antitumor activity of a phosphorothioate antisense oligodeoxynucleotide targeted against c-raf kinase
47. Phase I trial of C-raf antisense oligonucleotide ISIS 5132 (CGP 69846A) by 21-day continuous infusion (CIV) in patients with advanced cancer
48. Phase I trial of the c-Raf-1 antisense oligonucleotide (ODN) ISIS 5132 administered as a 21-day continuous IV infusion in combination with 5-fluorouracil (5-FU) and leucovorin (LV) as a daily x5 IV bolus
49. Gene therapy for pancreatic carcinoma: Local and distant antitumor effects after somatostatin receptor sst2 gene transfer
50. Sex steroid receptors and antisteroid agents in the treatment of pancreatic adenocarcinoma
51. Tamoxifen therapy in unresectable adenocarcinoma of the pancreas
52. Tamoxifen therapy in unresectable adenocarcinoma of the pancreas and papilla of Vater
53. Clinical trial of tamoxifan in patients with irresectable pancreatic adenocarcinoma, the Yorkshire Gastrointestinal Tumor Group
54. Hormonal treatment of pancreatic carcinoma, a phase II study of LHRH agonist goserelin plus hydrocortisone
55. LH-RH analogue treatment in adenocarcinoma of the pancreas, a phase II study
56. Treatment of patients with metastic pancreatic and gastrointestinal tumours with the somatostatin analogue sandostatin, a phase II study including endocrine effects
57. Low-dose octreotide treatment is not effective in patients with advanced pancreatic cancer
58. Matrix metalloproteinase inhibitors: Applications in oncology
59. Effect of eicosapentaenoic acid and other fatty acids on the growth in vitro of human pancreatic cancer cell lines